Logo

Merck to Use Numerate's In Silico Drug Design Platform

Mar 17, 2012
Premium

Numerate said this week that Merck will use its in silico drug design platform to generate small-molecule drug leads for an undisclosed cardiovascular disease target.

Financial details of the agreement were not disclosed.

Numerate's CEO Guido Lanza said in statement that the company was "pleased" to add Merck to its client list.

That list includes Boehringer Ingelheim, whose researchers are using the platform to generate drug leads for an unnamed infectious disease target (BI 12/09/11).

Filed under

Informatics
Merck
Breaking News
The Scan

International Team Proposes Checklist for Returning Genomic Research Results

Researchers in the European Journal of Human Genetics present a checklist to guide the return of genomic research results to study participants.

Study Presents New Insights Into How Cancer Cells Overcome Telomere Shortening

Researchers report in Nucleic Acids Research that ATRX-deficient cancer cells have increased activity of the alternative lengthening of telomeres pathway.

Researchers Link Telomere Length With Alzheimer's Disease

Within UK Biobank participants, longer leukocyte telomere length is associated with a reduced risk of dementia, according to a new study in PLOS One.

Nucleotide Base Detected on Near-Earth Asteroid

Among other intriguing compounds, researchers find the nucleotide uracil, a component of RNA sequences, in samples collected from the near-Earth asteroid Ryugu, as they report in Nature Communications.